Novartis deepens its industry leading pipeline with acquisition of Spinifex Pharmaceuticals, Inc.
- Details
- Category: Novartis
Novartis announced today that it has entered into an agreement to acquire Spinifex Pharmaceuticals, Inc. Spinifex Pharmaceuticals, Inc. is a US and Australian-based, privately held development stage company, focused on developing a peripheral approach to treat neuropathic pain such as EMA401, a novel angiotensin II Type 2 receptor (AT2R) antagonist.
Pfizer enters into agreement to acquire Nimenrix and Mencevax from GlaxoSmithKline
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) has entered into an agreement with GlaxoSmithKline (GSK) to acquire its quadrivalent meningitis ACWY vaccines, Nimenrix and Mencevax, for a total consideration of approximately $130 million (€115 million).
Novartis highlights strong innovation momentum at its second Meet Novartis Management investor day
- Details
- Category: Novartis
For its second "Meet Novartis Management" investor day, Novartis gathered more than 20 of its top executives from Pharmaceuticals, Alcon, Sandoz and NIBR, to meet with approximately 100 investors and analysts at the Novartis Institutes for BioMedical Research in Boston.
Roche employees unite to raise funds for children in need
- Details
- Category: Roche
Today, Roche (SIX: RO, ROG; OTCQX: RHHBY) employees participate in the 2015 Roche Children's Walk at more than 131 company sites across the world. The funds raised through the event will be used to support children in need, either in the local community or in Malawi in Southeast Africa, one of the world's least developed countries.
Bayer to divest Diabetes Care business to Panasonic Healthcare Holdings Co., Ltd. for EUR 1,022 million
- Details
- Category: Bayer
Bayer AG has entered into a definitive agreement to sell its Diabetes Care business to Panasonic Healthcare Holdings Co., Ltd., a company which is backed by funds sponsored by leading global investment firm KKR and the Panasonic Corporation. The total consideration for the transaction is EUR 1,022 million (JPY 138 billion).
Patients reporting better quality of communication by their physician show improved self-care
- Details
- Category: Boehringer Ingelheim
New research shows that the quality of patient-physician communication, at the moment when additional oral type 2 diabetes (T2D) medication is prescribed ('add-on'), is linked to future patient self-care and well-being.(1) Data from the IntroDia™ Survey have quantitatively demonstrated this link in the largest international survey of its kind, using responses from 4,235 people with T2D across 26 countries.*(1)
Get Ready. Get Set. Get Old.
- Details
- Category: Pfizer
Pfizer is challenging Americans to embrace aging as not an end, but a beginning - a time to fulfill old dreams and make new ones a reality. For graduation season 2015, "Get Ready. Get Set. Get Old." releases its "Commencement Day" video and new Get Old branding that serve as reminders of the inspiration, hopes and dreams that begin the next phase of every journey.
More Pharma News ...
- Amgen announces collaboration with Roche on cancer immunotherapy study with investigational medicines talimogene laherparepvec and atezolizumab
- Combination of Novartis drugs Tafinlar® and Mekinist® shows significant survival benefit in patients with metastatic melanoma
- AstraZeneca and Lilly to collaborate on Immuno-oncology combination clinical trial in solid tumours
- Pfizer announces $3 million grants program to further clinical research in advanced breast cancer
- Eureka Therapeutics Inc. and Boehringer Ingelheim announce a collaboration to identify next generation antibodies for cancer treatment
- AstraZeneca provides update on brodalumab development programme
- Novartis drug Afinitor® extended progression-free survival in Phase III trial in advanced gastrointestinal or lung neuroendocrine tumors